FCHI8,141.92-0.19%
GDAXI24,083.53-0.19%
DJI49,167.79-0.13%
XLE56.72-0.09%
STOXX50E5,860.32-0.39%
XLF51.71-0.19%
FTSE10,321.09-0.56%
IXIC24,887.100.20%
RUT2,788.190.04%
GSPC7,173.910.12%
Temp29.2°C
UV7.2
Feels33.1°C
Humidity62%
Wind11.9 km/h
Air QualityAQI 1
Cloud Cover25%
Rain0%
Sunrise06:00 AM
Sunset06:47 PM
Time3:34 PM
Cayman Journal
27 April 2026
Sign In
Markets13FInsidersPress ReleasesCompaniesPeopleReal EstateYachtAI Agents + MCPBusinessEconomyMarkets & FinanceTechnology
DEF 14ASEC Filing

Harmony Biosciences Holdings, Inc. — DEF 14A Filing

HRMY
April 3, 2026 at 12:00 AM

🧾 What This Document Is — Your Invitation to the Company's Big Meeting

This is a proxy statement (Form DEF 14A) for Harmony Biosciences Holdings, Inc. (HRMY). Think of it as the official guidebook and ballot for the company's annual shareholder meeting. The purpose is to give shareholders the information they need to vote on key company matters. It details what will be voted on, who is on the board, and how the company is governed.

📅 The Virtual Shareholder Meeting

The annual meeting will be held online on May 14, 2026, at 1:00 p.m. Eastern Time. Shareholders can attend, ask questions, and vote from anywhere via a live webcast. 👉 Why it matters: A virtual format means more shareholders can participate easily without travel, but you'll need your control number (on your notice or proxy card) to join.

🗳️ What You're Voting On (The 3 Main Proposals)

You have three main decisions to make:

  1. Elect Four Directors: Vote to elect four people to the board for a three-year term. The board recommends voting FOR Andreas Wicki, Geno Germano, Troy Ignelzi, and Ron Philip.
  2. Ratify the Auditor: Vote to approve Deloitte & Touche LLP as the company's independent accounting firm for 2026. The board recommends voting FOR.
  3. "Say-on-Pay" Vote: A non-binding, advisory vote to approve the pay packages for Harmony's top executives. The board recommends voting FOR.

👥 Who's on the Board? (Governance & Nominees)

The board oversees the company and is split into three classes. Here’s who is up for election or continuing their service:

  • The Four Nominees (to serve until 2029):
    • Andreas Wicki, Ph.D. (Age 67): CEO of HBM Healthcare Investments. Brings deep biotech investment experience.
    • Geno Germano (Age 65): Former pharmaceutical executive (Pfizer, Elucida Oncology). Adds decades of drug commercialization and leadership experience.
    • Troy Ignelzi (Age 58): CFO of Rapport Therapeutics. Former CFO of Karuna Therapeutics. Provides strong financial and life sciences CFO expertise.
    • Ron Philip (Age 52): Former CEO of Orbital Therapeutics and Spark Therapeutics. Adds operational and leadership experience from leading biotech companies.
  • Continuing Directors: Include Chairman Jeffrey Aronin (the company's founder), CEO Jeffrey Dayno, M.D., and other independent directors with finance, commercial, and governance expertise.

👉 Why it matters: The board provides strategic oversight. These nominees are being evaluated for their experience in finance, biotech leadership, and drug development, which are critical for a pharmaceutical company.

💼 Financial Oversight: The Auditor

The company's auditor is Deloitte & Touche LLP. For 2025, Harmony paid Deloitte $2.28 million in total fees ($1.59M for audit services and $0.69M for tax services). 👉 Why it matters: Shareholders ratify the auditor to ensure independent checks on the company's financial reporting. The fees show the scale and cost of this oversight.

🏛️ How the Company is Governed

  • Committees: The board has three key committees:
    • Audit Committee (oversees financials, risk, and auditors).
    • Compensation Committee (sets executive pay).
    • Nominating & Corporate Governance Committee (finds director candidates and oversees governance rules).
  • Independence: Most directors are independent, meaning they have no material relationship with the company outside of their board role. This is a key check on management.
  • Virtual Meeting Rules: The company has specific rules for the virtual meeting to ensure orderly conduct.

🔮 What's Next & Key Dates

  • Record Date (March 17, 2026): You must own shares by this date to vote.
  • Meeting Date (May 14, 2026): The annual meeting is held.
  • Deadline for 2027 Proposals (December 4, 2026): Shareholders who want to propose something for next year's meeting must do so by this date. 👉 Why it matters: These deadlines determine who can vote and what can be discussed at future meetings.

⚖️ The Big Picture

  • Strengths (👍): Strong board with relevant industry experts (ex-Pfizer, ex-CEO of biotechs). Clear governance structure with independent committees. A founder (Aronin) with deep company history is leading the board.
  • Risks (⚠️): The "say-on-pay" vote is advisory but can signal shareholder dissatisfaction. The company's strategy and executive performance are under continuous scrutiny.

🧠 The Analogy

This proxy statement is like the agenda and candidate list for a town hall meeting. The town (the company) is run by a council (the board). You, as a resident (shareholder), are invited to a virtual town hall to elect council members, approve the town's accountant, and give your opinion on the mayor's (executive team's) salary. The document gives you the resumes of the candidates and the rules of the meeting so you can make informed decisions.

🧩 Final Takeaway

Harmony Biosciences is holding its annual shareholder meeting to elect experienced directors, re-approve its auditor, and take an advisory vote on executive pay. The focus is on continuity and oversight, with a board composed largely of independent industry veterans guiding the company's strategy. Your vote, as a shareholder, helps shape this governance.